Financials in USD. Standardized financial statements.
A compact view of how GlobeImmune, Inc. turns revenue into operating income and net income.
| Metric | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|
| Revenue? | $6.46M | $5.97M | $22.52M | $14.64M | $5.11M | $4.07M |
| Revenue Growth? | +8.2% | -73.5% | +53.8% | +186.6% | +25.6% | 0.0% |
| Cost of Revenue? | $2.65M | $4.99M | $9.02M | $10,033 | $0 | $0 |
| Gross Profit? | $3.81M | $974,169 | $13.49M | $14.63M | $5.11M | $4.07M |
| Gross Margin? | +59.0% | +16.3% | +59.9% | +99.9% | +100.0% | +100.0% |
| Operating Expenses? | $9.22M | $11.79M | $14.83M | $18.61M | $17.70M | $19.82M |
| Operating Income? | -$2.77M | -$5.82M | $7.69M | -$3.97M | -$12.59M | -$15.75M |
| EBITDA? | -$2.58M | -$12.08M | $8.46M | -$1.09M | -$12.77M | -$14.42M |
| Income Before Tax | -$2.77M | -$16.26M | $9.59M | -$2.01M | -$13.73M | -$14.80M |
| Income Tax Expense | $0 | $3.89M | $115,765 | $0 | $1.13M | -$952,944 |
| Net Income? | -$2.77M | -$20.15M | $9.48M | -$2.01M | -$14.86M | -$14.79M |
| EPS? | $-0.48 | $-6.91 | $-35.64 | $-21.07 | $-155.37 | $-154.69 |
| Diluted EPS? | $-0.48 | $-6.91 | $-35.64 | $-21.07 | $-155.37 | $-154.69 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality